Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

28.95 -0.83 (-2.79%)

Streaming Delayed Price Updated: 11:08 AM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

32 33 Next >

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets

February 17, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap? ↗

February 17, 2023

The company's biggest moneymakers are soon to lose patent protection.

Via Investor's Business Daily

Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug ↗

February 13, 2023

Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug.

Via InvestorPlace

Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling ↗

February 13, 2023

The company only just gained approval for its depression drug in August.

Via Investor's Business Daily

Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims

February 09, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Why Teva Pharmaceutical Stock Is Sliding Today ↗

February 08, 2023

Investors were disappointed with the drugmaker's 2023 outlook.

Via The Motley Fool

Teva Pharmaceutical Stock Dives On Fourth-Quarter Miss, Light 2023 Guidance ↗

February 08, 2023

The company missed fourth-quarter estimates and issued light guidance.

Via Investor's Business Daily

Teva Pharmaceutical Industries (TEVA) Q4 2022 Earnings Call Transcript ↗

February 08, 2023

TEVA earnings call for the period ending December 31, 2022.

Via The Motley Fool

Teva Pharma Posts Lower Q4 Earnings, FY23 Outlook Within Expectations ↗

February 08, 2023

Via Benzinga

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

February 08, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026 ↗

February 08, 2023

These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite.

Via The Motley Fool

The 7 Best Growth Stocks to Buy for February 2023 ↗

February 06, 2023

Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors.

Via InvestorPlace

Analyst Ratings for Teva Pharmaceutical Indus ↗

January 19, 2023

Via Benzinga

3 Dirt Cheap Stocks to Buy in January ↗

January 14, 2023

Bargains can easily be found as the new year gets underway.

Via The Motley Fool

Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review ↗

January 27, 2023

Stocks reacted well to uneven earnings and economic reports.

Via Investor's Business Daily

Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed? ↗

January 26, 2023

Things aren't as bad as they might seem.

Via The Motley Fool

6 Great Stocks to Buy in 2023 and Hold Forever ↗

January 26, 2023

I own all six great businesses and don't plan to sell a single share.

Via The Motley Fool

How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback ↗

January 25, 2023

Catalyst is adding to its portfolio with a $160 million deal.

Via Investor's Business Daily

Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025 ↗

January 25, 2023

A 33% plunge in the Nasdaq Composite is the opportune time to scoop up these exceptional deals.

Via The Motley Fool

Dow, Nasdaq Boasting Triple-Digit Midday Lead ↗

January 23, 2023

Investors seem intent on leaving last week's losses behind, as earnings season heats up.

Via Talk Markets

Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product ↗

January 23, 2023

Via Benzinga

No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product ↗

January 23, 2023

Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023 ↗

January 19, 2023

Via Benzinga

Tesla To Rally Around 138%? Here Are 10 Other Analyst Forecasts For Thursday ↗

January 19, 2023

JP Morgan cut the price target for Apple Inc. (NASDAQ: AAPL) from $190 to $180. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to $133.70 in pre-market...

Via Benzinga

Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

January 19, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Organon Stock Scores Market Leadership With Jump To 83 RS Rating ↗

January 17, 2023

Organon sees its Relative Strength Rating reach the 80-plus level.

Via Investor's Business Daily

If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today ↗

January 13, 2023

The stock has gone on a wild ride over the past few years.

Via The Motley Fool

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023

January 12, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Most Active Equity Options For Midday - Wednesday, Jan. 11 ↗

January 11, 2023

Here are the most active equity options for midday.

Via Talk Markets

NVAX Stock Alert: What to Know as Novavax Names New CEO ↗

January 09, 2023

Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries.

Via InvestorPlace

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

32 33 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.